Requirements for multi-level systems pharmacology models to reach endusage: The case of type 2 diabetes

Interface Focus

Volumn 6, Issue 2, 2016, Pages

  Nyman, Elin ^a,b   Rozendaal, Yvonne J W ^c   Helmlinger, Gabriel ^b   Hamrén, Bengt ^d   Kjellsson, Maria C ^e   Strålfors, Peter ^a   Van Riel, Natal A W ^c   Gennemark, Peter ^b   Cedersund, Gunnar ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b ASTRAZENECA   (United Kingdom)

^c EINDHOVEN UNIVERSITY OF TECHNOLOGY   (Netherlands)

^d ASTRAZENECA R AND D   (Sweden)

^e UPPSALA UNIVERSITY   (Sweden)

Author keywords

Anti diabetic treatment; Decision support type 2 diabetes; Disease progression; Mathematical modelling; Systems pharmacology

Indexed keywords

EID: 84958818119     PISSN: 20428898     EISSN: 20428901     Source Type: Journal    
DOI: 10.1098/rsfs.2015.0075     Document Type: Review

References (81)

1. Hodgkin AL, Huxley AF. 1952 A quantitative description of membrane current and its application to conduction and excitation in nerve. J. Physiol. 117, 500–544. (doi:10.1113/jphysiol.1952.sp004764)
2. Del Castillo J, Katz B. 1954 Quantal components of the end-plate potential. J. Physiol. 124, 560–573. (doi:10.1113/jphysiol.1954.sp005129)
3. Noble D, Garny A, Noble PJ. 2012 How the Hodgkin–Huxley equations inspired the cardiac physiome project. J. Physiol. 590, 2613–2628. (doi:10.1113/jphysiol.2011.224238)
4. Kovatchev BP, Breton MD, Dalla Man C, Cobelli C. 2008 In silico model and computer simulation environment approximating the human glucose/ insulin utilization. Food and Drug Administration Master File MAF 1521.
5. Man CD, Micheletto F, Lv D, Breton M, Kovatchev B, Cobelli C. 2014 The UVA/PADOVA Type 1 diabetes simulator: new features. J. Diabetes Sci. Technol. 8, 26–34. (doi:10.1177/1932296813514502)
6. Hunter PJ, Crampin EJ, Nielsen PM. 2008 Bioinformatics, multiscale modeling and the IUPS physiome project. Brief Bioinformatics 9, 333–343. (doi:10.1093/bib/bbn024)
7. Mistry H. 2015 A new classifier-based strategy for in-silico ion-channel cardiac drug safety assessment. Front. Pharmacol. 6, 1–6. (doi:10.3389/fphar.2015.00059)
8. Britton OJ, Bueno-Orovio A, Van Ammel K, Lu HR, Towart R, Gallacher DJ, Rodriguez B. 2013 Experimentally calibrated population of models predicts and explains intersubject variability in cardiac cellular electrophysiology. Proc. Natl Acad. Sci. USA 110, E2098–E2105. (doi:10.1073/pnas.1304382110)
9. Brännmark C, Nyman E, Fagerholm S, Bergenholm L, Ekstrand EM, Cedersund G, Strålfors P. 2013 Insulin signaling in type 2 diabetes: experimental and modeling analyses reveal mechanisms of insulin resistance in human adipocytes. J. Biol. Chem. 288, 9867–9880. (doi:10.1074/jbc.M112.432062)
10. Nyman E, Rajan MR, Fagerholm S, Brannmark C, Cedersund G, Stralfors P. 2014 A single mechanism can explain network-wide insulin resistance in adipocytes from obese patients with type 2 diabetes. J. Biol. Chem. 289, 33215–33230. (doi:10.1074/jbc.M114.608927)
11. van der Graaf PH, Benson N. 2011 Systems pharmacology: bridging systems biology and pharmacokinetics-pharmacodynamics (PKPD) in drug discovery and development. Pharm. Res. 28, 1460–1464. (doi:10.1007/s11095-011-0467-9)
12. Ajmera I, Swat M, Laibe C, Novere NL, Chelliah V. 2013 The impact of mathematical modeling on the understanding of diabetes and related complications. CPT: Pharmacomet. Syst. Pharmacol. 2, e54. (doi:10.1038/psp.2013.30)
13. Cedersund G, Strålfors P. 2009 Putting the pieces together in diabetes research: towards a hierarchical model of whole-body glucose homeostasis. Eur. J. Pharm. Sci. 36, 91–104. (doi:10.1016/j.ejps.2008.10.027)
14. Nyman E, Cedersund G, Stralfors P. 2012 Insulin signaling—mathematical modeling comes of age. Trends Endocrinol. Metab. 23, 107–115. (doi:10.1016/j.tem.2011.12.007)
15. Landersdorfer CB, Jusko WJ. 2008 Pharmacokinetic/ pharmacodynamic modelling in diabetes mellitus. Clin. Pharmacokinet. 47, 417–448. (doi:10.2165/00003088-200847070-00001)
16. Palumbo P, Ditlevsen S, Bertuzzi A, De Gaetano A. 2013 Mathematical modeling of the glucose– insulin system: a review. Math. Biosci. 244, 69–81. (doi:10.1016/j.mbs.2013.05.006)
17. Palmer R, Nyman E, Penney M, Marley A, Cedersund G, Agoram B. 2014 Effects of IL-1bblocking therapies in type 2 diabetes mellitus: a quantitative systems pharmacology modeling approach to explore underlying mechanisms. CPT: Pharmacomet. Syst. Pharmacol. 3, e118. (doi:10.1038/psp.2014.16)
18. de Winter W, DeJongh J, Post T, Ploeger B, Urquhart R, Moules I, Eckland D, Danhof M. 2006 A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying type 2 diabetes mellitus. J. Pharmacokinet. Pharmacodyn. 33, 313–343. (doi:10.1007/s10928-006-9008-2)
19. Tiemann CA, Vanlier J, Hilbers PA, van Riel NA. 2011 Parameter adaptations during phenotype transitions in progressive diseases. BMC Syst. Biol. 5, 174. (doi:10.1186/1752-0509-5-174)
20. Tiemann CA, Vanlier J, Oosterveer MH, Groen AK, Hilbers PA, van Riel NA. 2013 Parameter trajectory analysis to identify treatment effects of pharmacological interventions. PLoS Comput. Biol. 9, e1003166. (doi:10.1371/journal.pcbi.1003166)
21. Hijmans BS et al. 2014 A systems biology approach reveals the physiological origin of hepatic steatosis induced by liver X receptor activation. FASEB J. 29, 1153–1164. (doi:10.1096/fj.14-254656)
22. Nyman E, Brännmark C, Palmér R, Brugård J, Nyström FH, Strålfors P, Cedersund G. 2011 A hierarchical whole-body modeling approach elucidates the link between in vitro insulin signaling and in vivo glucose homeostasis. J. Biol. Chem. 286, 26028–26041. (doi:10.1074/jbc.M110.188987)
23. Brännmark C, Palmér R, Glad ST, Cedersund G, Strålfors P. 2010 Mass and information feedbacks through receptor endocytosis govern insulin signaling as revealed using a parameter-free modeling framework. J. Biol. Chem. 285, 20171–20179. (doi:10.1074/jbc.M110.106849)
24. Kiselyov VV, Versteyhe S, Gauguin L, De Meyts P. 2009 Harmonic oscillator model of the insulin and IGF1 receptors’ allosteric binding and activation. Mol. Syst. Biol. 5, 243. (doi:10.1038/msb.2008.78)
25. Lodish MB. 2013 Clinical review: kinase inhibitors: adverse effects related to the endocrine system. J. Clin. Endocrinol. Metab. 98, 1333–1342. (doi:10.1210/jc.2012-4085)
26. Konig M, Bulik S, Holzhutter HG. 2012 Quantifying the contribution of the liver to glucose homeostasis: a detailed kinetic model of human hepatic glucose metabolism. PLoS Comput. Biol. 8, e1002577. (doi:10.1371/journal.pcbi.1002577)
27. Konig M, Holzhutter HG. 2012 Kinetic modeling of human hepatic glucose metabolism in type 2 diabetes mellitus predicts higher risk of hypoglycemic events in rigorous insulin therapy. J. Biol. Chem. 287, 36978–36989. (doi:10.1074/jbc.M112.382069)
28. Pedersen MG. 2010 A biophysical model of electrical activity in human beta-cells. Biophys. J. 99, 3200–3207. (doi:10.1016/j.bpj.2010.09.004)
29. Riz M, Braun M, Pedersen MG. 2014 Mathematical modeling of heterogeneous electrophysiological responses in human beta-cells. PLoS Comput. Biol. 10, e1003389. (doi:10.1371/journal.pcbi.1003389)
30. Fridlyand LE, Jacobson DA, Philipson LH. 2013 Ion channels and regulation of insulin secretion in human beta-cells: a computational systems analysis. Islets 5, 1–15. (doi:10.4161/isl.24166)
31. Divoli A, Mendonca EA, Evans JA, Rzhetsky A. 2011 Conflicting biomedical assumptions for mathematical modeling: the case of cancer metastasis. PLoS Comput. Biol. 7, e1002132. (doi:10.1371/journal.pcbi.1002132)
32. Davidian M, Giltinan DM. 1998 Nonlinear models for repeated measurement data, pxv, 359 p. Boca Raton, FL: Chapman & Hall/CRC.
33. Sheiner LB, Beal SL. 1980 Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data. J. Pharmacokinet. Biopharm. 8, 553–571. (doi:10.1007/BF01060053)
34. Bergman RN, Ider YZ, Bowden CR, Cobelli C. 1979 Quantitative estimation of insulin sensitivity. Am. J. Physiol. 236, E667–E677.
35. Dalla Man C, Rizza RA, Cobelli C. 2007 Meal simulation model of the glucose–insulin system. IEEE Trans. Biomed. Eng. 54, 1740–1749. (doi:10.1109/TBME.2007.893506)
36. Silber HE, Jauslin PM, Frey N, Karlsson MO. 2010 An integrated model for the glucose–insulin system. Basic Clin. Pharmacol. Toxicol. 106, 189–194. (doi:10.1111/j.1742-7843.2009.00510.x)
37. Silber HE, Jauslin PM, Frey N, Gieschke R, Simonsson US, Karlsson MO. 2007 An integrated model for glucose and insulin regulation in healthy volunteers and type 2 diabetic patients following intravenous glucose provocations. J. Clin. Pharmacol. 47, 1159–1171. (doi:10.1177/0091270007304457)
38. Jauslin PM, Silber HE, Frey N, Gieschke R, Simonsson US, Jorga K, Karlsson MO. 2007 An integrated glucose– insulin model to describe oral glucose tolerance test data in type 2 diabetics. J. Clin. Pharmacol. 47, 1244–1255. (doi:10.1177/0091270007302168)
39. Silber HE, Frey N, Karlsson MO. 2010 An integrated glucose–insulin model to describe oral glucose tolerance test data in healthy volunteers. J. Clin. Pharmacol. 50, 246–256. (doi:10.1177/0091270009341185)
40. Schneck KB, Zhang X, Bauer R, Karlsson MO, Sinha VP. 2013 Assessment of glycemic response to an oral glucokinase activator in a proof of concept study: application of a semi-mechanistic, integrated glucose–insulin–glucagon model. J. Pharmacokinet. Pharmacodyn. 40, 67–80. (doi:10.1007/s10928-012-9287-8)
41. Dansirikul C, Silber HE, Karlsson MO. 2008 Approaches to handling pharmacodynamic baseline responses. J. Pharmacokinet. Pharmacodyn. 35, 269–283. (doi:10.1007/s10928-008-9088-2)
42. Kjellsson MC, Cosson VF, Mazer NA, Frey N, Karlsson MO. 2013 A model-based approach to predict longitudinal HbA1c, using early phase glucose data from type 2 diabetes mellitus patients after antidiabetic treatment. J. Clin. Pharmacol. 53, 589–600. (doi:10.1002/jcph.86)
43. Jelic K, Hallgreen CE, Colding-Jorgensen M. 2009 A model of NEFA dynamics with focus on the postprandial state. Ann. Biomed. Eng. 37, 1897–1909. (doi:10.1007/s10439-009-9738-6)
44. Roy A, Parker RS. 2006 Dynamic modeling of free fatty acid, glucose, and insulin: an extended ‘minimal model’. Diabetes Technol. Ther. 8, 617–626. (doi:10.1089/dia.2006.8.617)
45. Roy A, Parker RS. 2007 Dynamic modeling of exercise effects on plasma glucose and insulin levels. J. Diabetes Sci. Technol. 1, 338–347. (doi:10.1177/193229680700100305)
46. Sips FL, Nyman E, Adiels M, Hilbers PA, Stralfors P, van Riel NA, Cedersund G. 2015 Model-based quantification of the systemic interplay between glucose and fatty acids in the postprandial state. PLoS ONE 10, e0135665. (doi:10.1371/journal.pone.0135665)
47. Gobel B, Langemann D, Oltmanns KM, Chung M. 2010 Compact energy metabolism model: brain controlled energy supply. J. Theor. Biol. 264, 1214–1224. (doi:S0022-5193(10)00108-6)
48. Gobel B, Langemann D. 2011 Systemic investigation of a brain-centered model of the human energy metabolism. Theory Biosci. 130, 5–18. (doi:10.1007/s12064-010-0105-9)
49. Gobel B, Oltmanns KM, Chung M. 2013 Linking neuronal brain activity to the glucose metabolism. Theor. Biol. Med. Model. 10, 50. (doi:10.1186/1742-4682-10-50)
50. Tura A, Muscelli E, Gastaldelli A, Ferrannini E, Mari A. 2014 Altered pattern of the incretin effect as assessed by modelling in individuals with glucose tolerance ranging from normal to diabetic. Diabetologia 57, 1199–1203. (doi:10.1007/s00125-014-3219-7)
51. Brubaker PL, Ohayon EL, D’Alessandro LM, Norwich KH. 2007 A mathematical model of the oral glucose tolerance test illustrating the effects of the incretins. Ann. Biomed. Eng. 35, 1286–1300. (doi:10.1007/s10439-007-9274-1)
52. Swameye I, Muller TG, Timmer J, Sandra O, Klingmuller U. 2003 Identification of nucleocytoplasmic cycling as a remote sensor in cellular signaling by databased modeling. Proc. Natl Acad. Sci. USA 100, 1028–1033. (doi:10.1073/pnas.0237333100)
53. van Riel NA, Sontag ED. 2006 Parameter estimation in models combining signal transduction and metabolic pathways: the dependent input approach. Syst. Biol. (Stevenage) 153, 263–274. (doi:10.1049/ip-syb:20050076)
54. De Gaetano A, Hardy T, Beck B, Abu-Raddad E, Palumbo P, Bue Valleskey J, Porksen N. 2008 Mathematical models of diabetes progression. Am. J. Physiol. Endocrinol. Metab. 295, E1462–E1479. (doi:10.1152/ajpendo.90444.2008)
55. Topp B, Promislow K, de Vries G, Miura RM, Finegood DT. 2000 A model of beta-cell mass, insulin, and glucose kinetics: pathways to diabetes. J. Theor. Biol. 206, 605–619. (doi:10.1006/jtbi. 2000.2150)
56. Hardy T, Abu-Raddad E, Porksen N, De Gaetano A. 2012 Evaluation of a mathematical model of diabetes progression against observations in the diabetes prevention program. Am. J. Physiol. Endocrinol. Metab. 303, E200–E212. (doi:10.1152/ajpendo.00421.2011)
57. Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JA, Seifert B, Mandrup-Poulsen T, Donath MY. 2007 Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 356, 1517–1526. (doi:10.1056/NEJMoa065213)
58. Larsen CM, Faulenbach M, Vaag A, Ehses JA, Donath MY, Mandrup-Poulsen T. 2009 Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 32, 1663–1668. (doi:10.2337/dc09-0533)
59. Ribbing J, Hamren B, Svensson MK, Karlsson MO. 2010 A model for glucose, insulin, and beta-cell dynamics in subjects with insulin resistance and patients with type 2 diabetes. J. Clin. Pharmacol. 50, 861–872. (doi:10.1177/0091270009349711)
60. Graham EJ, Adler FR. 2014 Long-term models of oxidative stress and mitochondrial damage in insulin resistance progression. J. Theor. Biol. 340, 238–250. (doi:10.1016/j.jtbi.2013.09.028)
61. Fernstrom JD, Choi S. 2008 The development of tolerance to drugs that suppress food intake. Pharmacol. Ther. 117, 105–122. (doi:10.1016/j.pharmthera.2007.09.001)
62. Woods SC, D’Alessio DA. 2008 Central control of body weight and appetite. J. Clin. Endocrinol. Metab. 93, S37–S50. (doi:10.1210/jc.2008-1630)
63. Lenard NR, Berthoud HR. 2008 Central and peripheral regulation of food intake and physical activity: pathways and genes. Obesity 16(3), S11–S22. (doi:10.1038/oby.2008.511)
64. Speakman JR et al. 2011 Set points, settling points and some alternative models: theoretical options to understand how genes and environments combine to regulate body adiposity. Dis. Models Mech. 4, 733–745. (doi:10.1242/dmm.008698)
65. Hall KD, Sacks G, Chandramohan D, Chow CC, Wang YC, Gortmaker SL, Swinburn BA. 2011 Quantification of the effect of energy imbalance on bodyweight. Lancet 378, 826–837. (doi:10.1016/S0140-6736(11)60812-X)
66. Kennedy GC. 1953 The role of depot fat in the hypothalamic control of food intake in the rat. Proc. R. Soc. Lond. B 140, 578–596. (doi:10.1098/rspb.1953.0009)
67. Tam J, Fukumura D, Jain RK. 2009 A mathematical model of murine metabolic regulation by leptin: energy balance and defense of a stable body weight. Cell Metab. 9, 52–63. (doi:10.1016/j.cmet.2008.11.005)
68. Gennemark P, Hjorth S, Gabrielsson J. 2015 Modeling energy intake by adding homeostatic feedback and drug intervention. J. Pharmacokinet. Pharmacodyn. 42, 79–96. (doi:10.1007/s10928- 014-9399-4)
69. Yu YH, Vasselli JR, Zhang Y, Mechanick JI, Korner J, Peterli R. 2015 Metabolic vs. hedonic obesity: a conceptual distinction and its clinical implications. Obes. Rev. 16, 234–247. (doi:10.1111/obr.12246)
70. Jullesson D, Johansson R, Rajan MR, Stralfors P, Cedersund G. 2015 Dominant negative inhibition data should be analyzed using mathematical modeling: reinterpreting data from insulin signaling. FEBS J. 282, 788–802. (doi:10.1111/febs.13182)
71. Nyman E, Lindgren I, Lovfors W, Lundengard K, Cervin I, Sjostrom TA, Altimiras J, Cedersund G. 2015 Mathematical modeling improves EC50 estimations from classical dose-response curves. FEBS J. 282, 951–962. (doi:10.1111/febs.13194)
72. Cedersund G. 2012 Conclusions via unique predictions obtained despite unidentifiability: new definitions and a general method. FEBS J. 279, 3513–3527. (doi:10.1111/j.1742-4658.2012.08725.x)
73. Vanlier J, Tiemann CA, Hilbers PA, van Riel NA. 2014 Optimal experiment design for model selection in biochemical networks. BMC Syst. Biol. 8, 20. (doi:10.1186/1752-0509-8-20)
74. Waters SB, Topp BG, Siler SQ, Alexander CM. 2009 Treatment with sitagliptin or metformin does not increase body weight despite predicted reductions in urinary glucose excretion. J. Diabetes Sci. Technol. 3, 68–82. (doi:10.1177/193229680900300108)
75. Karlsson M, Janzén D, Durrieu L, Colman-Lerner A, Kjellsson MC, Cedersund G. 2015 Nonlinear mixedeffects modelling for single cell estimation: when, why, and how to use it. BMC Syst. Biol. 9, 52. (doi:10.1186/s12918-015-0203-x)
76. Kłopotek M, Wierzchoń ST, Michalewicz M 2002 Intelligent information systems 2002: proceedings of the IIS’ 2002 Symposium, Sopot, Poland, June 3–6, 2002, x, 468 p. Heidelberg, Germany: Physica.
77. Turner APF, Karube I, Wilson GS. 1987 Biosensors: fundamentals and applications, pxvi, 770 p. Oxford, UK: Oxford University Press.
78. Gardner RM, Overhage JM, Steen EB, Munger BS, Holmes JH, Williamson JJ, Detmer DE, Directors ABO. 2009 Core content for the subspecialty of clinical informatics. J. Am. Med. Inf. Assoc. 16, 153–157. (doi:10.1197/jamia.M3045)
79. Uribe GA, Blobel B, Lopez DM, Ruiz AA. 2015 Specializing architectures for the type 2 diabetes mellitus care use cases with a focus on process management. Stud. Health Technol. Informatics 211, 132–142.
80. Lind L, Karlsson D, Fridlund B. 2008 Patients’ use of digital pens for pain assessment in advanced palliative home healthcare. Int. J. Med. Informatics 77, 129–136. (doi:10.1016/j.ijmedinf.2007.01.013)
81. Parekh WA, Ashley D, Chubb B, Gillies H, Evans M. 2015 Approach to assessing the economic impact of insulinrelated hypoglycaemia using the novel local impact of hypoglycaemia tool. Diabetes Med. 35, 1156–1166. (doi:10.1111/dme.12771)